GS 834356
Alternative Names: GS-834356Latest Information Update: 07 Aug 2023
At a glance
- Originator Gilead Sciences; Novo Nordisk
- Class Small molecules
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 07 Aug 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (Combination therapy) in Denmark (SC) (Novo Nordisk pipeline, August 2023)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA
- 18 Mar 2021 Gilead Sciences and Novo Nordisk expands their clinical collaboration agreement